Press Releases
Eisai Receives Complete Response Letter from FDA for Rabeprazole Sodium Extended-Release Capsules
Eisai announced that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under...
Press Releases
15 Merck & Co senior executives join the eyeforpharma Sales Force Effectiveness forum
15 senior directors registered for eyeforpharma’s SFE 2011 (29-31 March, Dusseldorf) meeting. The Event Director Kate Eversole stated, “I am overwhelmed by the amount of interest for this show- we have already sold 1/3 of our tickets- mostly to...
Press Releases
Protagen at the Personalized Medicine and Diagnostics Europe Congress 2011
Protagen AG, a specialist for GMP-compliant protein analysis and in-vitro diagnostics is presenting at the Personalized Medicine and Diagnostics Europe Congress in London. Dr. Stefan Müllner, CEO of Protagen AG will discuss the latest achievements in personalized medicine together...
Press Releases
PIA Vietnam to return in March 2011 with broader focus
The next edition of PIA Vietnam, a premier trade event focused on process engineering and instrumentation as well as laboratory and scientific equipment, will be taking place at Saigon Exhibition & Convention Center (SECC), Ho Chi Minh City, from...
Press Releases
Allan Mackintosh, PMAP Performance Coach, Grunenthal, on the evolving KAM approach
Allan Mackintosh, PMAP Performance Coach, Gruenthal believes that the KAM approach is where we will see most change within the pharma industry over the next 5-10 years. It is undeniable that the customer base is more complex than ever...
Press Releases
Roche personalized investigational medicine shows survival benefit in advanced skin cancer
Roche announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma. Study participants who received...
Press Releases
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients
ARIAD Pharmaceuticals, Inc. announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
